Comparative Immunohistochemical Study of P63, SMA, CD10 and Calponin in Distinguishing In Situ from Invasive Breast Carcinoma

Abdallah, Dina; Deeb, Nevine Mf El

doi:10.4172/2155-9929.1000342

Cited by 2 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant difference in staining was noted between highgrade and low-grade DCIS. This was similar to studies done by Khazai et al [4] and Abdallah et al [7]. The discontinuous staining in these cases may be due to ductal expansion associated with DCIS, resulting in fading of the myoepithelial cells.…”

Section: Discussionsupporting

confidence: 91%

“…Different cytokeratins are described in the luminal and basal cell types, whereas myoepithelial cells express basal cell-type cytokeratins, smooth muscle actin, calponin, and p63. An intact myoepithelial layer is often seen in benign and in situ lesions, whereas loss of this layer is considered a diagnostic feature of invasive cancer [4][5][6][7]. p63 is a specific nuclear marker for myoepithelial cells of the breast with no known cross-reactivity and, therefore, may aid in differentiating benign lesions from malignant lesions [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Study of the Immunohistochemical Expression of p63 in Benign Lesions and Carcinoma of the Breast at a Tertiary Hospital in South India

Prabhu,

Rai,

Nayak

et al. 2023

Cureus

View full text Add to dashboard Cite

Background: Invasive breast carcinoma is among the most common female cancers worldwide, causing high morbidity and mortality. Considerable disagreement in the interpretation of diagnostically challenging breast lesions based on histology alone has been documented. One of the essential histopathological findings that help distinguish benign from malignant lesions is the presence of the myoepithelial cell layer. Myoepithelial markers such as tumor protein 63 (p63) help distinguish invasive carcinoma from benign proliferations. p63 antibody is superior to other myoepithelial markers as it selectively stains the nuclei and is negative in stromal cells.Objective: To study the expression of p63 in various histological subtypes and grades of breast carcinomas.Methods: After routine hematoxylin and eosin stain, 65 cases of breast lesions were subjected to immunohistochemistry for p63 antigen using Novacastra ready-to-use monoclonal antibody p6. All cases were analyzed for p63 expression, and its staining arrangement was interpreted.Results: In all benign lesions, immunoreactivity was noted in the myoepithelial cells, forming a continuous layer surrounding the luminal epithelial cells. The benign papillary lesions showed p63 staining in the fibrovascular core of the papillary fronds and at the periphery. A few single myoepithelial cells stained by p63 were also seen scattered discontinuously in ductal carcinoma in situ (DCIS). All invasive carcinomas and encapsulated papillary carcinomas were completely devoid of peripheral p63 staining of myoepithelial cells.Conclusion: p63 is a specific nuclear marker of myoepithelial cells in the breast and can, therefore, aid in distinguishing invasive ductal carcinoma from DCIS or rare questionable hyperplastic lesions. They also play a significant role in distinguishing various papillary lesions of the breast and, hence, can be incorporated into routine reporting for definitive diagnosis and accurate treatment.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Study of the Immunohistochemical Expression of p63 in Benign Lesions and Carcinoma of the Breast at a Tertiary Hospital in South India

Prabhu,

Rai,

Nayak

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Abdallah et al . recently reported computational measurements of the sensitivity of calponin, P63, CD10, and αSMA in demonstrating the myoepithelium of DCIS lesions, with results comparable to our “naïve method” [18]. …”

Section: Resultssupporting

confidence: 56%

A method for quantification of calponin expression in myoepithelial cells in immunohistochemical images of ductal carcinoma in situ

Gray¹,

Mitchell

Jindal

et al. 2018

2018 IEEE 15th International Symposium on Biomedical Imaging (ISBI 2018)

View full text Add to dashboard Cite

Ductal carcinoma in situ (DCIS) is breast cancer confined within mammary ducts, surrounded by an intact myoepithelial cell layer that prevents local invasion. A DCIS diagnosis confers increased lifetime risk of developing invasive breast cancer (IBC) and results in surgical excision with radiation, and possibly endocrine- or chemo-therapy. DCIS is known to be over treated, with associated co-morbidities. Biomarkers are needed that delineate patients at low risk of DCIS progression from patients requiring more aggressive treatment. Investigating the role of myoepithelial cell differentiation in barrier function is anticipated to provide insight into DCIS progression and delineate between low and high risk lesions. Here, we develop a high throughput technique to assess loss of myoepithelial differentiation markers. This method facilitates automated analysis of a clinically relevant histopathologic feature, as demonstrated by a high correlation with pathologist annotation (r = 0.959), and further, contributes analytical foundations to a multiplexed immunohistochemistry (IHC) approach.

show abstract

Comparative Immunohistochemical Study of P63, SMA, CD10 and Calponin in Distinguishing In Situ from Invasive Breast Carcinoma

Cited by 2 publications

References 10 publications

Study of the Immunohistochemical Expression of p63 in Benign Lesions and Carcinoma of the Breast at a Tertiary Hospital in South India

Study of the Immunohistochemical Expression of p63 in Benign Lesions and Carcinoma of the Breast at a Tertiary Hospital in South India

A method for quantification of calponin expression in myoepithelial cells in immunohistochemical images of ductal carcinoma in situ

Contact Info

Product

Resources

About